医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Thermo Fisher Scientific Expands Global Footprint to Support Cell and Gene Therapy Clinical Trials in Japan

2016年10月03日 PM09:30
このエントリーをはてなブックマークに追加


 

TOKYO

To help meet increasing demand for cell and gene therapy clinical trial support around the globe, Thermo Fisher Scientific, the world leader in serving science, today announced the expansion of its Fisher BioServices cryogenic service capabilities in Japan. This expansion enables its customers to seamlessly conduct clinical trials across multiple geographies and provides patients around the world with access to life changing therapies. As a leading service provider to the cell and gene therapy community, Fisher BioServices is uniquely positioned with the experience, resources, and global expertise to support its customers on their path towards commercialization.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161003005027/en/

Thermo Fisher Scientific Expands Global Footprint to Support Cell and Gene Therapy Clinical Trials i ...

Thermo Fisher Scientific Expands Global Footprint to Support Cell and Gene Therapy Clinical Trials in Japan (Photo: Business Wire)

The facility in Tokyo was expanded to include cryogenic storage and logistics by utilizing a combination of proven components and validated procedures developed with years of experience in the cell and gene therapy business. The new modules within this facility allow Fisher BioServices to configure and replicate each site to meet the specific requirements of individual clinical trials with minimal variation, regardless of volume or geographic location. The facility is also supported by a global comprehensive and integrated Quality System based on regulatory requirements, industry best practices and trained personnel.

“Japan is an increasingly important market for cell and gene therapy companies conducting clinical trials,” said Dennis Barger, Fisher BioServices vice president and general manager. “The addition of cryogenic services to this facility in Japan, combined with our existing capabilities in Europe and the US, enables us to seamlessly support our customers’ global trials as they develop and commercialize their therapies.”

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of $17 billion and more than 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161003005027/en/

CONTACT

Thermo Fisher Scientific
Marcia K. Goff, +1-508-902-7041
marcia.goff@thermofisher.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • InFo 124M – スイス製の白内障手術用EDOF IOL
  • 武田药品工业株式会社开始对ARIAD Pharmaceuticals, Inc.所有流通股进行现金要约收购
  • Dr. Reddy’s to Release Q3 FY17 Results on Feb 4, 2017
  • ファインデックス、愛媛大工学部・京都大医学部との共同研究により新たな検査手法を用いた視野検査システムの開発に着手
  • 全球患者安全与科技年度峰会将首次以高清格式向美国以外地区进行流媒体直播